Zynerba Pharmaceuticals Inc (ZYNE) : Cormorant Asset Management scooped up 118,435 additional shares in Zynerba Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 475,035 shares of Zynerba Pharmaceuticals Inc which is valued at $4,873,859.Zynerba Pharmaceuticals Inc makes up approximately 0.62% of Cormorant Asset Management’s portfolio.
Other Hedge Funds, Including , Nexthera Capital Lp sold out all of its stake in ZYNE during the most recent quarter. The investment firm sold 15,000 shares of ZYNE which is valued $153,900. Alpine Partners Vi added ZYNE to its portfolio by purchasing 16,491 company shares during the most recent quarter which is valued at $169,198. Zynerba Pharmaceuticals Inc makes up approx 0.08% of Alpine Partners Vi’s portfolio. Tiaa Cref Investment Management sold out all of its stake in ZYNE during the most recent quarter. The investment firm sold 7,863 shares of ZYNE which is valued $80,674.Vanguard Group Inc reduced its stake in ZYNE by selling 1,896 shares or 0.92% in the most recent quarter. The Hedge Fund company now holds 204,215 shares of ZYNE which is valued at $2,095,246. California State Teachers Retirement System sold out all of its stake in ZYNE during the most recent quarter. The investment firm sold 7,528 shares of ZYNE which is valued $70,989.
Zynerba Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company has two product candidates including ZYN002 and ZYN001 which represent cannabinoid therapeutics for several indications including refractory epilepsy Fragile X syndrome (FXS) osteoarthritis (OA) fibromyalgia and peripheral neuropathic pain. ZYN002 is a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In preclinical animal studies ZYN002’s permeation enhancer increased delivery of CBD through the layers of the skin and into the circulatory system. ZYN001 is a pro-drug of delta-9-tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. In preclinical animal studies ZYN001 demonstrated effective skin permeation with sustained delivery and rapid conversion of ZYN001 to THC.